We would love to hear your thoughts about our site and services, please take our survey here.
Last patient hasn't been confirmed being enrolled yet. Then at least 6 weeks on from that. Then results, so prob looking at Jan at the eariest tbh IMHO DYOR.
Patients is required with this share, a good solid gentle tick up is very understated
Hi JSP, I hope all goes well and your mother in law is on the mend soon.
The criteria for the trial are very specific. Due to its design. More information should be available for a update on trial
Still no rns confirming that home trial has completed the final recruitment of patients. 14 day treatment plan so at least 2 weeks from final patient. then going off last time round, 6- 8 weeks to get results processed and rns'd. So alot left of phase 2. If results show similar to that of hospital arm, then with P3 in the pipeline it may just get EUA
Start generating income with the decline,( new processing plant being funded and built at the same time) my input. . If potential 20 year mine life would make sense, as could telfer last another 20 years as is?
No they happy when it is positive and people are buying. Lol
Surely peer review can only be a positive
Now it has been published, sng001 should now be considered on Par with remdesvir at least. Bring on the P3 and emergency use approval.
He didn't specify a year.
20 May 2020
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Avacta and Medusa19 Enter into a Distribution Agreement for COVID-19 Antigen Test
Global, exclusive, direct-to-consumer sales and marketing agreement for COVID-19 self-testing
Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased to announce that it has entered into an exclusive distribution agreement with Medusa19 Limited ("Medusa19") for direct-to-consumer sales of a saliva-based rapid test for the COVID-19 antigen.
Avacta recently announced a partnership with Cytiva (formerly GE Healthcare Life Sciences) to develop a saliva-based rapid antigen test to indicate whether a person has the COVID-19 infection which will be in the form of a simple test strip. The test is intended to give a result within minutes and for use by both healthcare professionals and consumers.
The Group has agreed an exclusive distribution agreement with Medusa19 for the supply of the COVID-19 rapid test direct to consumers globally, subject to the necessary regulatory approvals. Medusa19 has been established by Richard Hughes and Mahmud Kamani, both founder shareholders of Boohoo.com and shareholders of Avacta1, to build a global consumer self-testing business. Medusa19's initial focus will be on COVID-19 home testing and it is currently investing in global e-commerce, logistics and customer support infrastructure in preparation for Avacta's COVID-19 test launch. Medusa19 will also have non-exclusive rights to supply the tests to businesses for workforce testing. The distribution agreement includes a profit-sharing arrangement.
The global demand for rapid antigen tests, which will be critical to lockdown exit strategies around the world in order to get healthy, non-contagious people back to work, could be many millions of tests per month. There will also be an ongoing need for several years for this type of testing as the disease recurs.
They got a favourable placing allocation around 50p If I can remember, maybe wrong tho.
Any mention of avacta? If so or a glimpse of a la el for confirmation, initial batchs from cytiva were for initial validation.
Took about 4 weeks to come up with current spec, of affirmers quick turnaround
Boris also said thr next few weeks for the test.
Just a very naughty boy.
I am sure he brought in May time of before as well, must be trading it.
GH has ties with thor, I am lead to believe. Used to work for them
Means this project is fully funded, no further outlay by UFO to invest into other projects has slightly derisked this share for me now. Onwards
Let the 10% crew back in on the cheap
Squits